Our findings, consistent with previous reports, demonstrate that SB225002, a selective CXCR2 antagonist, exerts potent anti-tumor activity in NB cell lines and 3D spheroid models, which more closely recapitulate in vivo tumor physiology [26]. The gene discussed is CXCR2; the disease is neoplasm.